BofA analyst Michael Cherny maintains a Purchase score on AmerisourceBergen after the DOJ filed a civil criticism alleging the corporate didn’t disclose suspicious opioid and different managed substance orders. The information is “not one thing that might/ought to create one other significant overhang” on condition that a further lawsuit on the opioid entrance “isn’t overly stunning,” it’s a part of an ongoing course of and the corporate, primarily based on its response, is “combating closely,” Cherny tells buyers.
Revealed first on TheFly
See right this moment’s best-performing shares on TipRanks >>
Learn Extra on ABC:
